| Sean M Burket, CRNP | |
|
255 West Lancaster Avenue, Bldg 2 - Suite 328, Paoli, PA 19301-1766 | |
| (610) 647-2400 | |
| (610) 647-3902 |
| Full Name | Sean M Burket |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Acute Care |
| Location | 255 West Lancaster Avenue, Paoli, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154510568 | NPI | - | NPPES |
| 1031628290001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | SP009817 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sean M Burket, CRNP 207 N Broad St, 3rd Floor, Philadelphia, PA 19107-1500 Ph: (267) 479-4142 | Sean M Burket, CRNP 255 West Lancaster Avenue, Bldg 2 - Suite 328, Paoli, PA 19301-1766 Ph: (610) 647-2400 |
News Archive
Ludwig-Maximilians-Universitaet (LMU) in Munich researchers have developed a novel type of nanoparticle that efficiently and selectively kills cancer cells, thus opening up new therapeutic options for the treatment of tumors.
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Zimmer Holdings, Inc. today reported financial results for the quarter ended September 30, 2009. The Company reported third quarter net sales of $976 million, an increase of 2.4% reported and 3.6% constant currency over the third quarter of 2008. Diluted earnings per share for the quarter were $0.70 reported and $0.88 adjusted, a decrease of 9.3% adjusted from the prior year period.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
The future of colon cancer screening may be surprisingly simple. ColoMarker, an innovative blood test to detect the early stages of colon cancer is generating plenty of attention from a wide audience, including from some of the world's leading researchers in cancer biomarkers and gastrointestinal medicine.
› Verified 5 days ago
Jamie L Dillinger, C.R.N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 21 Industrial Blvd, Suite 101, Paoli, PA 19301 Phone: 610-251-0300 Fax: 610-251-0304 | |
Mrs. Lynn B Wolff, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 255 W Lancaster Ave, Paoli, PA 19301 Phone: 484-565-1600 Fax: 610-647-2006 | |
Angela Foster, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1776 E Lancaster Ave, Paoli, PA 19301 Phone: 610-647-4366 | |
Elizabeth Wray, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 30 S Valley Rd Ste 101, Paoli, PA 19301 Phone: 267-553-5063 | |
Hayley Suzann Swanson, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 11 Industrial Blvd Ste 103, Paoli, PA 19301 Phone: 610-786-3200 | |
Holly Marks, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 255 W Lancaster Ave, Paoli, PA 19301 Phone: 484-565-1000 | |
Kelly N Jones, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2 Industrial Blvd Ste 200, Paoli, PA 19301 Phone: 610-647-2400 Fax: 610-647-3902 |